VAX 24
Alternative Names: 24-Valent Pneumococcal Conjugate Vaccine - Vaxcyte; Pneumococcal conjugate vaccine - Vaxcyte; SVX-24; VAX-24Latest Information Update: 09 Oct 2025
At a glance
- Originator SutroVax
- Developer Sutro Biopharma; Vaxcyte
- Class Conjugate vaccines; Pneumococcal vaccines; Protein vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Pneumococcal infections
- Discontinued Otitis media
Most Recent Events
- 09 Oct 2025 Phase-III clinical trials in Pneumococcal infections (Parenteral) (Prior to October 2025) (Sutro Biopharma pipeline, October 2025)
- 25 Aug 2025 Vaxcyte completes a phase II trial for Pneumococcal infections (Prevention, In Infants) in USA (IM, Injection) (NCT05844423)
- 31 Mar 2025 Adverse events and immunogenicity data from a phase II trial in Pneumococcal infections released by Vaxcyte